CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has transformed biology more profoundly than any tool since PCR. Adapted from a natural bacterial immune system, CRISPR-Cas9 uses a guide RNA to direct the Cas9 enzyme to a specific DNA sequence, where it makes a precise double-strand break. The cell's repair mechanisms then introduce desired changes — deletions, insertions, or replacements — at the cut site. The system is remarkably simple, inexpensive, and versatile compared to earlier gene-editing technologies.
The technology's impact spans medicine, agriculture, and industrial biotechnology. In December 2023, the FDA approved Casgevy (developed by Vertex Pharmaceuticals and CRISPR Therapeutics) as the first CRISPR-based gene therapy, treating sickle cell disease by editing patients' own blood stem cells. Editas Medicine, Intellia Therapeutics, and Beam Therapeutics are advancing CRISPR therapies for genetic diseases, cancer, and cardiovascular conditions. Agricultural applications include disease-resistant crops and improved livestock.
CRISPR technology continues to evolve rapidly. Base editing (developed by David Liu at the Broad Institute) enables single-letter DNA changes without cutting both strands. Prime editing offers even more precise editing capabilities. CRISPRi and CRISPRa allow genes to be silenced or activated without permanently altering DNA. Each advance expands the toolkit available to synthetic biologists, making biological systems increasingly programmable. The technology's inventors, Jennifer Doudna and Emmanuelle Charpentier, received the 2020 Nobel Prize in Chemistry. For deeper coverage, see SynBioIntel.